

Peter Kolkhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8820821/publications.pdf>

Version: 2024-02-01

57
papers

7,114
citations

87723

38
h-index

149479

56
g-index

59
all docs

59
docs citations

59
times ranked

2992
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229. | 13.9 | 1,148 |
| 2 | Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263. | 13.9 | 599 |
| 3 | Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884. | 3.8 | 523 |
| 4 | Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463. | 1.0 | 419 |
| 5 | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484. | 1.0 | 341 |
| 6 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114. | 1.0 | 274 |
| 7 | Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 69-78. | 0.8 | 265 |
| 8 | Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161. | 1.0 | 249 |
| 9 | Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases. <i>ChemMedChem</i> , 2012, 7, 1385-1403. | 1.6 | 194 |
| 10 | 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. <i>Journal of Endocrinology</i> , 2017, 234, T125-T140. | 1.2 | 174 |
| 11 | Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552. | 1.6 | 171 |
| 12 | A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule. <i>Journal of Biological Chemistry</i> , 2010, 285, 29932-29940. | 1.6 | 157 |
| 13 | Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. <i>Hypertension</i> , 2018, 71, 599-608. | 1.3 | 149 |
| 14 | Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. <i>Molecular and Cellular Endocrinology</i> , 2012, 350, 310-317. | 1.6 | 129 |
| 15 | Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356. | 1.4 | 127 |
| 16 | Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. <i>Journal of Biological Chemistry</i> , 2015, 290, 21876-21889. | 1.6 | 116 |
| 17 | Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344. | 1.4 | 112 |
| 18 | Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260. | 2.6 | 112 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. <i>Kidney International</i> , 2018, 93, 1344-1355. | 2.6 | 109 |
| 20 | Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 271-305. | 0.9 | 102 |
| 21 | Nonsteroidal antagonists of the mineralocorticoid receptor. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 417-424. | 1.0 | 100 |
| 22 | Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 870-878. | 1.3 | 92 |
| 23 | Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237. | 3.0 | 89 |
| 24 | Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447. | 1.6 | 86 |
| 25 | Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. <i>American Journal of Nephrology</i> , 2021, 52, 642-652. | 1.4 | 80 |
| 26 | Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152. | 1.2 | 74 |
| 27 | Rationale and design of ARTS: a randomized, double-blind study of BAY 948862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675. | 2.9 | 72 |
| 28 | Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. <i>Hypertension</i> , 2016, 67, 717-723. | 1.3 | 69 |
| 29 | Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1216-1226. | 3.0 | 68 |
| 30 | Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NF- κ B Pathway. <i>Hypertension</i> , 2017, 70, 1148-1156. | 1.3 | 67 |
| 31 | Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. <i>FASEB Journal</i> , 2011, 25, 968-978. | 0.2 | 65 |
| 32 | Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3220-3234. | 2.7 | 65 |
| 33 | Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. <i>Frontiers in Pharmacology</i> , 2018, 9, 1131. | 1.6 | 61 |
| 34 | Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 402-411. | 0.8 | 59 |
| 35 | A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. <i>Circulation Journal</i> , 2016, 80, 1113-1122. | 0.7 | 54 |
| 36 | Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 398-404. | 3.0 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023. | 0.4 | 50 |
| 38 | Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1546-1555. | 1.7 | 44 |
| 39 | The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. <i>FASEB Journal</i> , 2020, 34, 12450-12465. | 0.2 | 38 |
| 40 | Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. <i>Pharmacological Research</i> , 2021, 172, 105859. | 3.1 | 37 |
| 41 | Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2399-2407. | 2.2 | 36 |
| 42 | The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. <i>PLoS ONE</i> , 2017, 12, e0184888. | 1.1 | 34 |
| 43 | The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. <i>Biochemical Pharmacology</i> , 2019, 168, 173-183. | 2.0 | 33 |
| 44 | Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 124-133. | 0.9 | 32 |
| 45 | Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. <i>American Journal of Nephrology</i> , 2021, 52, 588-601. | 1.4 | 31 |
| 46 | Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1141-1157. | 1.9 | 26 |
| 47 | Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005. | 2.9 | 23 |
| 48 | Corticosteroid receptors adopt distinct cyclical transcriptional signatures. <i>FASEB Journal</i> , 2018, 32, 5626-5639. | 0.2 | 22 |
| 49 | Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241. | 0.7 | 17 |
| 50 | Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. <i>European Journal of Heart Failure</i> , 2020, 23, 743-750. | 2.9 | 16 |
| 51 | Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. <i>ESC Heart Failure</i> , 2020, 7, 3983-3995. | 1.4 | 13 |
| 52 | Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. <i>FASEB Journal</i> , 2021, 35, e21314. | 0.2 | 12 |
| 53 | Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628. <i>PLoS ONE</i> , 2015, 10, e0145666. | 1.1 | 12 |
| 54 | Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 44-52. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Finerenone Reduces Renal ROR γ t ⁺ T Cells and Protects against Cardiorenal Damage. American Journal of Nephrology, 2022, 53, 552-564. | 1.4 | 6 |
| 56 | Abstract O55: Benefit of Mineralocorticoid Receptor Antagonism in Acute Kidney Injury: Role of Smooth Muscle Rac1. Hypertension, 2016, 68, . | 1.3 | 0 |
| 57 | Abstract P298: Finerenone Protects Against the Acute and Chronic Consequences of Renal Ischemia/reperfusion Injury. Hypertension, 2016, 68, . | 1.3 | 0 |